Last reviewed · How we verify
non-responders
Samsung Medical Center is conducting multiple clinical trials, including Phase 3 studies on a deuterated psilocin analog (CYB003) for major depressive disorder and guselkumab for Crohn's disease. The center also explores various other conditions, such as catatonic features in adolescents with profound autism and immune responses to vaccines.
At a glance
| Generic name | non-responders |
|---|---|
| Also known as | SSRI nonresponders |
| Sponsor | Samsung Medical Center |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- non-responders CI brief — competitive landscape report
- non-responders updates RSS · CI watch RSS
- Samsung Medical Center portfolio CI